Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial
Authors' conclusion
Tirzepatide improves therapeutic target attainment compared with semaglutide in type 2 diabetes. Longer trials are needed to confirm benefits on long-term prognosis.
Study context
- Population
- Adults with T2D in the SURPASS-2 trial
- Participants
- 1,879 adults
- Comparison
- Tirzepatide vs semaglutide
- Primary endpoint
- Attainment of standard (HbA1c <53 mmol/mol [7%], BP <140/90 mmHg, LDL-C <1.8 mmol/l, >10% weight loss) and intensive (HbA1c <48 mmol/mol [6.5%], BP <130/80 mmHg, LDL-C <1.4 mmol/l, >15% weight loss) therapeutic targets
- Follow-up
- 40 weeks
Methodological detailspost hoc analysis, phase 3
- Post hoc analysis
- Phase 3
Primary result
As reported in the abstract
≥3 standard targets met
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Specific targets, tirzepatide vs semaglutide · 40 weeksTirzepatidevs SemaglutideHbA1c <53 mmol/mol [7%] | 1.50 (1.12–2.00) | |
| Specific targets, tirzepatide vs semaglutide · 40 weeksTirzepatidevs SemaglutideHbA1c <48 mmol/mol [6.5%] | 1.88 (1.49–2.36) | |
| Specific targets, tirzepatide vs semaglutide · 40 weeksTirzepatidevs SemaglutideWeight loss >10% | 2.72 (2.14–3.47) | |
| Specific targets, tirzepatide vs semaglutide · 40 weeksTirzepatidevs SemaglutideWeight loss >15% | 3.86 (2.69–5.55) | |
| Specific targets, tirzepatide vs semaglutide · 40 weeksTirzepatidevs SemaglutideIntensive BP target | 1.45 (1.17–1.81) | |
| 0.20.5125Odds ratio (log scale) |
| Outcome | Semaglutide |
|---|---|
| ≥3 intensive targets met · 40 weeks | 8% |
≥3 intensive targets met · 40 weeks
- Tirzepatide (15%, 20% and 29%) vs semaglutide
Original publication
Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. Diabetologia. Published 19 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →